Status:

RECRUITING

Role of the Immune Environment in Response to Therapy in Breast Cancer

Lead Sponsor:

Abramson Cancer Center at Penn Medicine

Conditions:

Breast Cancer

ER Positive Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
  • Exclusion criteria:
  • Males Children Pregnant individuals

Exclusion

    Key Trial Info

    Start Date :

    October 3 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2032

    Estimated Enrollment :

    300 Patients enrolled

    Trial Details

    Trial ID

    NCT05396612

    Start Date

    October 3 2022

    End Date

    December 31 2032

    Last Update

    July 8 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Abramson Cancer Center

    Philadelphia, Pennsylvania, United States, 19104

    Role of the Immune Environment in Response to Therapy in Breast Cancer | DecenTrialz